Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Accounts Payables (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Accounts Payables for 10 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables fell 77.09% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 77.09%, and an annual FY2024 reading of $7.3 million, up 430.19% over the prior year.
  • Accounts Payables was $1.4 million for Q3 2025 at Spero Therapeutics, up from $780000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.3 million in Q4 2024 and bottomed at $583000.0 in Q1 2023.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Accounts Payables plummeted 87.8% in 2023, then soared 452.13% in 2024.
  • Year by year, Accounts Payables stood at $1.1 million in 2021, then plummeted by 43.96% to $617000.0 in 2022, then surged by 123.34% to $1.4 million in 2023, then soared by 430.19% to $7.3 million in 2024, then plummeted by 80.91% to $1.4 million in 2025.
  • Business Quant data shows Accounts Payables for SPRO at $1.4 million in Q3 2025, $780000.0 in Q2 2025, and $1.8 million in Q1 2025.